1011 related articles for article (PubMed ID: 33564768)
1. Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies.
Tada T; Dcosta BM; Samanovic-Golden M; Herati RS; Cornelius A; Mulligan MJ; Landau NR
bioRxiv; 2021 Feb; ():. PubMed ID: 33564768
[TBL] [Abstract][Full Text] [Related]
2. Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
Tada T; Dcosta BM; Samanovic MI; Herati RS; Cornelius A; Zhou H; Vaill A; Kazmierski W; Mulligan MJ; Landau NR
mBio; 2021 Jun; 12(3):e0069621. PubMed ID: 34060334
[TBL] [Abstract][Full Text] [Related]
3. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.
Wu K; Werner AP; Moliva JI; Koch M; Choi A; Stewart-Jones GBE; Bennett H; Boyoglu-Barnum S; Shi W; Graham BS; Carfi A; Corbett KS; Seder RA; Edwards DK
bioRxiv; 2021 Jan; ():. PubMed ID: 33501442
[TBL] [Abstract][Full Text] [Related]
4. Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera.
Tada T; Zhou H; Dcosta BM; Samanovic MI; Mulligan MJ; Landau NR
iScience; 2021 Nov; 24(11):103341. PubMed ID: 34723159
[TBL] [Abstract][Full Text] [Related]
5. B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.
Zhou H; Dcosta BM; Samanovic MI; Mulligan MJ; Landau NR; Tada T
mBio; 2021 Aug; 12(4):e0138621. PubMed ID: 34311587
[TBL] [Abstract][Full Text] [Related]
6. Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera toward SARS-CoV-2 viruses.
Hein S; Herrlein ML; Mhedhbi I; Bender D; Haberger V; Benz N; Eisert J; Stingl J; Dreher M; Oberle D; Schulze J; Mache C; Budt M; Hildt C; Wolff T; Hildt E
Allergy; 2022 Jul; 77(7):2080-2089. PubMed ID: 34820854
[TBL] [Abstract][Full Text] [Related]
7. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
[TBL] [Abstract][Full Text] [Related]
8. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera.
Xie X; Liu Y; Liu J; Zhang X; Zou J; Fontes-Garfias CR; Xia H; Swanson KA; Cutler M; Cooper D; Menachery VD; Weaver S; Dormitzer PR; Shi PY
bioRxiv; 2021 Jan; ():. PubMed ID: 33532771
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.
Xie X; Liu Y; Liu J; Zhang X; Zou J; Fontes-Garfias CR; Xia H; Swanson KA; Cutler M; Cooper D; Menachery VD; Weaver SC; Dormitzer PR; Shi PY
Nat Med; 2021 Apr; 27(4):620-621. PubMed ID: 33558724
[TBL] [Abstract][Full Text] [Related]
10. Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant.
Edara VV; Norwood C; Floyd K; Lai L; Davis-Gardner ME; Hudson WH; Mantus G; Nyhoff LE; Adelman MW; Fineman R; Patel S; Byram R; Gomes DN; Michael G; Abdullahi H; Beydoun N; Panganiban B; McNair N; Hellmeister K; Pitts J; Winters J; Kleinhenz J; Usher J; O'Keefe JB; Piantadosi A; Waggoner JJ; Babiker A; Stephens DS; Anderson EJ; Edupuganti S; Rouphael N; Ahmed R; Wrammert J; Suthar MS
bioRxiv; 2021 Feb; ():. PubMed ID: 33655254
[TBL] [Abstract][Full Text] [Related]
11. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
Jangra S; Ye C; Rathnasinghe R; Stadlbauer D; ; Krammer F; Simon V; Martinez-Sobrido L; García-Sastre A; Schotsaert M
medRxiv; 2021 Jan; ():. PubMed ID: 33532796
[TBL] [Abstract][Full Text] [Related]
12. SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity.
Neerukonda SN; Vassell R; Lusvarghi S; Wang R; Echegaray F; Bentley L; Eakin AE; Erlandson KJ; Katzelnick LC; Weiss CD; Wang W
bioRxiv; 2021 Nov; ():. PubMed ID: 34790980
[TBL] [Abstract][Full Text] [Related]
13. B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies.
Zhou H; Dcosta BM; Samanovic MI; Mulligan MJ; Landau NR; Tada T
bioRxiv; 2021 Mar; ():. PubMed ID: 33791698
[TBL] [Abstract][Full Text] [Related]
14. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
[TBL] [Abstract][Full Text] [Related]
15. Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies.
Tada T; Dcosta BM; Zhou H; Vaill A; Kazmierski W; Landau NR
bioRxiv; 2021 Feb; ():. PubMed ID: 33619484
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies.
Diamond M; Chen R; Xie X; Case J; Zhang X; VanBlargan L; Liu Y; Liu J; Errico J; Winkler E; Suryadevara N; Tahan S; Turner J; Kim W; Schmitz A; Thapa M; Wang D; Boon A; Pinto D; Presti R; O'Halloran J; Kim A; Deepak P; Fremont D; Corti D; Virgin H; Crowe J; Droit L; Ellebedy A; Shi PY; Gilchuk P
Res Sq; 2021 Feb; ():. PubMed ID: 33594356
[TBL] [Abstract][Full Text] [Related]
17. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
18. Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected.
Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Monari C; Luciani Pasqua B; Dragoni F; Schiaroli E; Zazzi M; Francisci D
J Infect; 2021 Oct; 83(4):467-472. PubMed ID: 34320390
[TBL] [Abstract][Full Text] [Related]
19. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
[TBL] [Abstract][Full Text] [Related]
20. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
